CSL

Company Overview

CSL is a global biotechnology company offering a wide range of specialty drugs, such as those for nephrology and iron deficiency, vaccines to prevent influenza, and treatments for hemophilia and immunological deficiencies. It operates through three business areas, including CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring manufactures, markets, and distributes plasma products, gene therapies, and recombinants. CSL Vifor manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology.

CSL Seqirus is a provider of influenza vaccines.  CSL’s egg-based and cell-based manufacturing facilities produce more than 100 million doses of influenza vaccines annually. CSL Seqirus collaborates with the WHO Collaborating Centre in Melbourne, Australia, to prepare vaccine seeds and potency reagents made publicly available to support the annual seasonal influenza vaccine epidemic.

Financial Highlights (FY 2024)

Company's Business Segments

• CSL Behring : Immunology, Hematology, Respiratory, Albumin
• CSL Seqirus : Egg based vaccines, Cell culture vaccines, Adjuvanted egg based vaccines, Pandemic, Other (including in-license)
• CSL Vifor : Iron deficiency and Iron deficiency anemia, Nephrology